Cover Image
Market Research Report
Product code 
1101967

Asia Pacific Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type, By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028

Published: | KBV Research | 130 Pages | Delivery time: 1-2 business days

Price

Back to Top
Asia Pacific Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type, By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028
Published: June 30, 2022
KBV Research
Content info: 130 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

The Asia Pacific Peptide Therapeutics Market would witness market growth of 7.3% CAGR during the forecast period (2022-2028).

PEGylation, serum albumin binding, glycosylation, cyclization, and lipidation are some of the peptide modifications used to extend half-life. PEGylation is the covalent bonding of polyethylene glycol (PEG) chains to peptides, which helps to enhance molecular weight while also limiting enzymatic breakdown due to steric hindrance induced by the PEG. PEGylation has several advantages in pharmaceutical applications, including enhanced water solubility, high solution mobility, low toxicity, and low immunogenicity. This, however, is dependent on the connected PEG's molecular weight. PEGylation as a strategy to improve half-life has been proved numerous times.

Attaching glycosyl (carbohydrate) units to the peptide is another chemical alteration that aids in peptide distribution to target sites. Carbohydrates can be added to peptides to change their physiological characteristics and increase their bioavailability. Increased metabolic stability along with facilitated transport across cell membranes are two advantages of this approach, but one of the most appealing features is its potential to promote oral absorption. Because of limited absorption and quick breakdown and elimination, peptides have lower oral availability of less than 1-2%, making this technique appealing. N- and O-glycosylation, in which carbohydrates are connected to the peptide, occurs naturally, with N-glycosylation forming an amide bond through the amine group of an asparagine residue.

Lung cancer, China's top cause of cancer death, has seen a dramatic increase in incidence and mortality rates in recent years, with geographic and gender inequalities as a result of differences in socioeconomic and lifestyle growth. Smoking, air pollution, as well as occupational characteristics are all linked to lung cancer. However, lung cancer incidence and mortality could be reduced by behavioral interventions, such as smoking cessation and screening.

As per the National Library of Medicines, in 2017, cancer caused around 62.9 million disability-adjusted life years (DALYs) in China. The most significant contribution was made by lung cancer, which was followed by stomach cancer, liver cancer, and esophageal cancer. China's success in lowering liver and stomach malignancies has been witnessed. However, China still has a high rate of lung cancer and a growing rate of malignancies associated with a westernized lifestyle, such as colorectal cancer, whereas Japan and South Korea have both reduced their rates of colorectal cancer and lung cancer.

Furthermore, compared to Japan and South Korea, China has a lower age-standardized cancer occurrence but higher cancer death and DALY rates. Due to peptide therapy's characteristics of being efficient in the treatment of cancer, the demand and adoption of this approach are increasing. Therefore, the growth of the regional market is flourishing.

The China market dominated the Asia Pacific Peptide Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,384.4 million by 2028. The Japan market is experiencing a CAGR of 6.6% during (2022 - 2028). Additionally, The India market would exhibit a CAGR of 7.9% during (2022 - 2028).

Based on Type, the market is segmented into Innovative and Generic. Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Innovative
  • Generic

By Route of Administration

  • Parenteral Route
  • Pulmonary
  • Mucosal
  • Oral Route
  • Others

By Synthesis Technology

  • Liquid Phase Peptide Synthesis (LPPS)
  • Solid Phase Peptide Synthesis (SPPS)
  • Hybrid Technology

By Type of Manufacturers

  • In-house
  • Outsourced

By Application

  • Metabolic
  • Cardiovascular Disorder
  • GIT & Renal
  • Antiinfection & Dermatology
  • Respiratory
  • Central Nervous System
  • Cancer
  • Pain
  • Others

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled

  • Eli Lilly And Company
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Lonza Group AG
  • Amgen, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.1 Objectives
  • 1.2 Market Scope
  • 1.3 Segmentation
    • 1.3.1 Asia Pacific Peptide Therapeutics Market, by Type
    • 1.3.2 Asia Pacific Peptide Therapeutics Market, by Route of Administration
    • 1.3.3 Asia Pacific Peptide Therapeutics Market, by Synthesis Technology
    • 1.3.4 Asia Pacific Peptide Therapeutics Market, by Type of Manufacturers
    • 1.3.5 Asia Pacific Peptide Therapeutics Market, by Application
    • 1.3.6 Asia Pacific Peptide Therapeutics Market, by Country
  • 1.4 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition and scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
    • 3.2.4 Approvals and Trails
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)

Chapter 4. Asia Pacific Peptide Therapeutics Market by Type

  • 4.1 Asia Pacific Innovative Market by Country
  • 4.2 Asia Pacific Generic Market by Country

Chapter 5. Asia Pacific Peptide Therapeutics Market by Route of Administration

  • 5.1 Asia Pacific Parenteral Route Market by Country
  • 5.2 Asia Pacific Pulmonary Market by Country
  • 5.3 Asia Pacific Mucosal Market by Country
  • 5.4 Asia Pacific Oral Route Market by Country
  • 5.5 Asia Pacific Others Market by Country

Chapter 6. Asia Pacific Peptide Therapeutics Market by Synthesis Technology

  • 6.1 Asia Pacific Liquid Phase Peptide Synthesis (LPPS) Market by Country
  • 6.2 Asia Pacific Solid Phase Peptide Synthesis (SPPS) Market by Country
  • 6.3 Asia Pacific Hybrid Technology Market by Country

Chapter 7. Asia Pacific Peptide Therapeutics Market by Type of Manufacturers

  • 7.1 Asia Pacific In-house Market by Country
  • 7.2 Asia Pacific Outsourced Market by Country

Chapter 8. Asia Pacific Peptide Therapeutics Market by Application

  • 8.1 Asia Pacific Metabolic Market by Country
  • 8.2 Asia Pacific Cardiovascular Disorder Market by Country
  • 8.3 Asia Pacific GIT & Renal Market by Country
  • 8.4 Asia Pacific Antiinfection & Dermatology Market by Country
  • 8.5 Asia Pacific Respiratory Market by Country
  • 8.6 Asia Pacific Central Nervous System Market by Country
  • 8.7 Asia Pacific Cancer Market by Country
  • 8.8 Asia Pacific Pain Market by Country
  • 8.9 Asia Pacific Others Market by Country

Chapter 9. Asia Pacific Peptide Therapeutics Market by Country

  • 9.1 China Peptide Therapeutics Market
    • 9.1.1 China Peptide Therapeutics Market by Type
    • 9.1.2 China Peptide Therapeutics Market by Route of Administration
    • 9.1.3 China Peptide Therapeutics Market by Synthesis Technology
    • 9.1.4 China Peptide Therapeutics Market by Type of Manufacturers
    • 9.1.5 China Peptide Therapeutics Market by Application
  • 9.2 Japan Peptide Therapeutics Market
    • 9.2.1 Japan Peptide Therapeutics Market by Type
    • 9.2.2 Japan Peptide Therapeutics Market by Route of Administration
    • 9.2.3 Japan Peptide Therapeutics Market by Synthesis Technology
    • 9.2.4 Japan Peptide Therapeutics Market by Type of Manufacturers
    • 9.2.5 Japan Peptide Therapeutics Market by Application
  • 9.3 India Peptide Therapeutics Market
    • 9.3.1 India Peptide Therapeutics Market by Type
    • 9.3.2 India Peptide Therapeutics Market by Route of Administration
    • 9.3.3 India Peptide Therapeutics Market by Synthesis Technology
    • 9.3.4 India Peptide Therapeutics Market by Type of Manufacturers
    • 9.3.5 India Peptide Therapeutics Market by Application
  • 9.4 South Korea Peptide Therapeutics Market
    • 9.4.1 South Korea Peptide Therapeutics Market by Type
    • 9.4.2 South Korea Peptide Therapeutics Market by Route of Administration
    • 9.4.3 South Korea Peptide Therapeutics Market by Synthesis Technology
    • 9.4.4 South Korea Peptide Therapeutics Market by Type of Manufacturers
    • 9.4.5 South Korea Peptide Therapeutics Market by Application
  • 9.5 Singapore Peptide Therapeutics Market
    • 9.5.1 Singapore Peptide Therapeutics Market by Type
    • 9.5.2 Singapore Peptide Therapeutics Market by Route of Administration
    • 9.5.3 Singapore Peptide Therapeutics Market by Synthesis Technology
    • 9.5.4 Singapore Peptide Therapeutics Market by Type of Manufacturers
    • 9.5.5 Singapore Peptide Therapeutics Market by Application
  • 9.6 Malaysia Peptide Therapeutics Market
    • 9.6.1 Malaysia Peptide Therapeutics Market by Type
    • 9.6.2 Malaysia Peptide Therapeutics Market by Route of Administration
    • 9.6.3 Malaysia Peptide Therapeutics Market by Synthesis Technology
    • 9.6.4 Malaysia Peptide Therapeutics Market by Type of Manufacturers
    • 9.6.5 Malaysia Peptide Therapeutics Market by Application
  • 9.7 Rest of Asia Pacific Peptide Therapeutics Market
    • 9.7.1 Rest of Asia Pacific Peptide Therapeutics Market by Type
    • 9.7.2 Rest of Asia Pacific Peptide Therapeutics Market by Route of Administration
    • 9.7.3 Rest of Asia Pacific Peptide Therapeutics Market by Synthesis Technology
    • 9.7.4 Rest of Asia Pacific Peptide Therapeutics Market by Type of Manufacturers
    • 9.7.5 Rest of Asia Pacific Peptide Therapeutics Market by Application

Chapter 10. Company Profiles

  • 10.1 Eli Lilly And Company
    • 10.1.1 Company Overview
    • 10.1.2 Financial Analysis
    • 10.1.3 Regional Analysis
    • 10.1.4 Research & Development Expenses
    • 10.1.5 Recent strategies and developments:
      • 10.1.5.1 Partnerships, Collaborations, and Agreements:
      • 10.1.5.2 Acquisition and Mergers:
      • 10.1.5.3 Approvals and Trails:
  • 10.2 AstraZeneca PLC
    • 10.2.1 Company Overview
    • 10.2.2 Financial Analysis
    • 10.2.3 Regional Analysis
    • 10.2.4 Research & Development Expenses
    • 10.2.5 Recent strategies and developments:
      • 10.2.5.1 Partnerships, Collaborations, and Agreements:
      • 10.2.5.2 Acquisition and Mergers:
  • 10.3 Teva Pharmaceutical Industries Ltd.
    • 10.3.1 Company Overview
    • 10.3.2 Financial Analysis
    • 10.3.3 Regional Analysis
    • 10.3.4 Research & Development Expenses
    • 10.3.5 Recent strategies and developments:
      • 10.3.5.1 Product Launches and Product Expansions:
      • 10.3.5.2 Approvals and Acquisitions:
  • 10.4 Novartis AG
    • 10.4.1 Company Overview
    • 10.4.2 Financial Analysis
    • 10.4.3 Segmental and Regional Analysis
    • 10.4.4 Research & Development Expense
    • 10.4.5 Recent strategies and developments:
      • 10.4.5.1 Acquisition and Mergers:
      • 10.4.5.2 Approvals and Trails:
  • 10.5 Pfizer, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Financial Analysis
    • 10.5.3 Regional & Segmental Analysis
    • 10.5.4 Research & Development Expense
    • 10.5.5 Recent strategies and developments:
      • 10.5.5.1 Acquisition and Mergers:
  • 10.6 Sanofi S.A.
    • 10.6.1 Company Overview
    • 10.6.2 Financial Analysis
    • 10.6.3 Segmental and Regional Analysis
    • 10.6.4 Research & Development Expense
    • 10.6.5 Recent strategies and developments:
      • 10.6.5.1 Partnerships, Collaborations, and Agreements:
  • 10.7 GlaxoSmithKline PLC
    • 10.7.1 Company Overview
    • 10.7.2 Financial Analysis
    • 10.7.3 Segmental and Regional Analysis
    • 10.7.4 Research & Development Expense
  • 10.8 Takeda Pharmaceutical Company Limited
    • 10.8.1 Company Overview
    • 10.8.2 Financial Analysis
    • 10.8.3 Regional Analysis
    • 10.8.4 Research & Development Expense
    • 10.8.5 Recent strategies and developments:
      • 10.8.5.1 Partnerships, Collaborations, and Agreements:
      • 10.8.5.2 Approvals and Trails:
  • 10.9 Lonza Group AG
    • 10.9.1 Company Overview
    • 10.9.2 Financial Analysis
    • 10.9.3 Segmental and Regional Analysis
    • 10.9.4 Research & Development Expenses
  • 10.10. Amgen, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Financial Analysis
    • 10.10.3 Regional Analysis
    • 10.10.4 Research & Development Expenses
    • 10.10.5 Recent strategies and developments:
      • 10.10.5.1 Partnerships, Collaborations, and Agreements:

LIST OF TABLES

  • TABLE 1 Asia Pacific Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 2 Asia Pacific Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 3 Partnerships, Collaborations and Agreements- Peptide Therapeutics Market
  • TABLE 4 Acquisition and Mergers- Peptide Therapeutics Market
  • TABLE 5 Approvals and trails- Peptide Therapeutics Market
  • TABLE 6 Asia Pacific Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 7 Asia Pacific Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 8 Asia Pacific Innovative Market by Country, 2018 - 2021, USD Million
  • TABLE 9 Asia Pacific Innovative Market by Country, 2022 - 2028, USD Million
  • TABLE 10 Asia Pacific Generic Market by Country, 2018 - 2021, USD Million
  • TABLE 11 Asia Pacific Generic Market by Country, 2022 - 2028, USD Million
  • TABLE 12 Asia Pacific Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 13 Asia Pacific Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 14 Asia Pacific Parenteral Route Market by Country, 2018 - 2021, USD Million
  • TABLE 15 Asia Pacific Parenteral Route Market by Country, 2022 - 2028, USD Million
  • TABLE 16 Asia Pacific Pulmonary Market by Country, 2018 - 2021, USD Million
  • TABLE 17 Asia Pacific Pulmonary Market by Country, 2022 - 2028, USD Million
  • TABLE 18 Asia Pacific Mucosal Market by Country, 2018 - 2021, USD Million
  • TABLE 19 Asia Pacific Mucosal Market by Country, 2022 - 2028, USD Million
  • TABLE 20 Asia Pacific Oral Route Market by Country, 2018 - 2021, USD Million
  • TABLE 21 Asia Pacific Oral Route Market by Country, 2022 - 2028, USD Million
  • TABLE 22 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 23 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 24 Asia Pacific Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 25 Asia Pacific Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 26 Asia Pacific Liquid Phase Peptide Synthesis (LPPS) Market by Country, 2018 - 2021, USD Million
  • TABLE 27 Asia Pacific Liquid Phase Peptide Synthesis (LPPS) Market by Country, 2022 - 2028, USD Million
  • TABLE 28 Asia Pacific Solid Phase Peptide Synthesis (SPPS) Market by Country, 2018 - 2021, USD Million
  • TABLE 29 Asia Pacific Solid Phase Peptide Synthesis (SPPS) Market by Country, 2022 - 2028, USD Million
  • TABLE 30 Asia Pacific Hybrid Technology Market by Country, 2018 - 2021, USD Million
  • TABLE 31 Asia Pacific Hybrid Technology Market by Country, 2022 - 2028, USD Million
  • TABLE 32 Asia Pacific Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 33 Asia Pacific Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 34 Asia Pacific In-house Market by Country, 2018 - 2021, USD Million
  • TABLE 35 Asia Pacific In-house Market by Country, 2022 - 2028, USD Million
  • TABLE 36 Asia Pacific Outsourced Market by Country, 2018 - 2021, USD Million
  • TABLE 37 Asia Pacific Outsourced Market by Country, 2022 - 2028, USD Million
  • TABLE 38 Asia Pacific Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 39 Asia Pacific Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 40 Asia Pacific Metabolic Market by Country, 2018 - 2021, USD Million
  • TABLE 41 Asia Pacific Metabolic Market by Country, 2022 - 2028, USD Million
  • TABLE 42 Asia Pacific Cardiovascular Disorder Market by Country, 2018 - 2021, USD Million
  • TABLE 43 Asia Pacific Cardiovascular Disorder Market by Country, 2022 - 2028, USD Million
  • TABLE 44 Asia Pacific GIT & Renal Market by Country, 2018 - 2021, USD Million
  • TABLE 45 Asia Pacific GIT & Renal Market by Country, 2022 - 2028, USD Million
  • TABLE 46 Asia Pacific Antiinfection & Dermatology Market by Country, 2018 - 2021, USD Million
  • TABLE 47 Asia Pacific Antiinfection & Dermatology Market by Country, 2022 - 2028, USD Million
  • TABLE 48 Asia Pacific Respiratory Market by Country, 2018 - 2021, USD Million
  • TABLE 49 Asia Pacific Respiratory Market by Country, 2022 - 2028, USD Million
  • TABLE 50 Asia Pacific Central Nervous System Market by Country, 2018 - 2021, USD Million
  • TABLE 51 Asia Pacific Central Nervous System Market by Country, 2022 - 2028, USD Million
  • TABLE 52 Asia Pacific Cancer Market by Country, 2018 - 2021, USD Million
  • TABLE 53 Asia Pacific Cancer Market by Country, 2022 - 2028, USD Million
  • TABLE 54 Asia Pacific Pain Market by Country, 2018 - 2021, USD Million
  • TABLE 55 Asia Pacific Pain Market by Country, 2022 - 2028, USD Million
  • TABLE 56 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 57 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 58 Asia Pacific Peptide Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 59 Asia Pacific Peptide Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 60 China Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 61 China Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 62 China Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 63 China Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 64 China Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 65 China Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 66 China Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 67 China Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 68 China Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 69 China Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 70 China Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 71 China Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 72 Japan Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 73 Japan Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 74 Japan Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 75 Japan Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 76 Japan Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 77 Japan Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 78 Japan Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 79 Japan Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 80 Japan Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 81 Japan Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 82 Japan Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 83 Japan Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 84 India Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 85 India Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 86 India Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 87 India Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 88 India Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 89 India Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 90 India Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 91 India Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 92 India Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 93 India Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 94 India Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 95 India Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 96 South Korea Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 97 South Korea Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 98 South Korea Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 99 South Korea Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 100 South Korea Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 101 South Korea Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 102 South Korea Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 103 South Korea Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 104 South Korea Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 105 South Korea Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 106 South Korea Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 107 South Korea Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 108 Singapore Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 109 Singapore Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 110 Singapore Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 111 Singapore Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 112 Singapore Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 113 Singapore Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 114 Singapore Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 115 Singapore Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 116 Singapore Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 117 Singapore Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 118 Singapore Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 119 Singapore Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 120 Malaysia Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 121 Malaysia Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 122 Malaysia Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 123 Malaysia Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 124 Malaysia Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 125 Malaysia Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 126 Malaysia Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 127 Malaysia Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 128 Malaysia Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 129 Malaysia Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 130 Malaysia Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 131 Malaysia Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 132 Rest of Asia Pacific Peptide Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 133 Rest of Asia Pacific Peptide Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 134 Rest of Asia Pacific Peptide Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 135 Rest of Asia Pacific Peptide Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 136 Rest of Asia Pacific Peptide Therapeutics Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 137 Rest of Asia Pacific Peptide Therapeutics Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 138 Rest of Asia Pacific Peptide Therapeutics Market by Synthesis Technology, 2018 - 2021, USD Million
  • TABLE 139 Rest of Asia Pacific Peptide Therapeutics Market by Synthesis Technology, 2022 - 2028, USD Million
  • TABLE 140 Rest of Asia Pacific Peptide Therapeutics Market by Type of Manufacturers, 2018 - 2021, USD Million
  • TABLE 141 Rest of Asia Pacific Peptide Therapeutics Market by Type of Manufacturers, 2022 - 2028, USD Million
  • TABLE 142 Rest of Asia Pacific Peptide Therapeutics Market by Application, 2018 - 2021, USD Million
  • TABLE 143 Rest of Asia Pacific Peptide Therapeutics Market by Application, 2022 - 2028, USD Million
  • TABLE 144 Key Information - Eli Lilly And Company
  • TABLE 145 KEY INFORMATION - ASTRAZENECA PLC
  • TABLE 146 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 147 Key Information - Novartis AG
  • TABLE 148 Key Information - Pfizer, Inc.
  • TABLE 149 Key Information - Sanofi S.A.
  • TABLE 150 Key Information - GlaxoSmithKline PLC
  • TABLE 151 Key Information - Takeda Pharmaceutical Company Limited
  • TABLE 152 Key Information - Lonza Group AG
  • TABLE 153 Key Information - Amgen, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 KBV Cardinal Matrix
  • FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
  • FIG 4 Recent strategies and developments: Eli Lilly And Company
  • FIG 5 Recent strategies and developments: AstraZeneca PLC
  • FIG 6 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
  • FIG 7 Recent strategies and developments: Novartis AG